Zevra Therapeutics (ZVRA) to Release Quarterly Earnings on Tuesday

Key Points

• Zevra Therapeutics is scheduled to release its Q2 2025 earnings on August 12th, with analysts expecting earnings of $0.65 per share and revenue of $22.49 million.
• The company's last quarter saw an earnings per share of ($0.06), surpassing estimates significantly, while revenue reached $20.40 million, above the projected $16.96 million.
• Current institutional ownership stands at 35.03%, with recent activity including the purchase of 16,700 shares by Strs Ohio valued at approximately $125,000.

Zevra Therapeutics (NASDAQ:ZVRA - Get Free Report) will likely be issuing its Q2 2025 quarterly earnings data after the market closes on Tuesday, August 12th. Analysts expect Zevra Therapeutics to post earnings of $0.65 per share and revenue of $22.49 million for the quarter.

Zevra Therapeutics (NASDAQ:ZVRA - Get Free Report) last posted its quarterly earnings results on Tuesday, May 13th. The company reported ($0.06) EPS for the quarter, topping analysts' consensus estimates of ($0.21) by $0.15. The business had revenue of $20.40 million during the quarter, compared to the consensus estimate of $16.96 million. Zevra Therapeutics had a negative return on equity of 201.05% and a negative net margin of 226.78%. During the same period last year, the firm earned ($0.40) earnings per share. On average, analysts expect Zevra Therapeutics to post $-2 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Zevra Therapeutics Stock Down 0.2%

NASDAQ:ZVRA traded down $0.03 during trading hours on Tuesday, hitting $11.23. 179,942 shares of the company's stock traded hands, compared to its average volume of 632,404. The company has a debt-to-equity ratio of 1.46, a quick ratio of 2.93 and a current ratio of 3.02. Zevra Therapeutics has a twelve month low of $6.19 and a twelve month high of $13.16. The stock's fifty day moving average price is $10.16 and its two-hundred day moving average price is $8.58. The firm has a market cap of $613.78 million, a P/E ratio of -5.91 and a beta of 1.87.

Institutional Trading of Zevra Therapeutics

A hedge fund recently bought a new stake in Zevra Therapeutics stock. Strs Ohio purchased a new position in shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Free Report) in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 16,700 shares of the company's stock, valued at approximately $125,000. Institutional investors own 35.03% of the company's stock.

Analyst Upgrades and Downgrades

ZVRA has been the topic of a number of research reports. Cantor Fitzgerald upped their price target on shares of Zevra Therapeutics from $25.00 to $29.00 and gave the company an "overweight" rating in a research note on Thursday, July 10th. Wall Street Zen lowered shares of Zevra Therapeutics from a "strong-buy" rating to a "buy" rating in a report on Sunday, July 20th. Citigroup reissued an "outperform" rating on shares of Zevra Therapeutics in a research report on Wednesday, May 14th. Finally, HC Wainwright assumed coverage on shares of Zevra Therapeutics in a report on Wednesday, July 2nd. They set a "buy" rating and a $26.00 price objective for the company. Nine investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company has a consensus rating of "Buy" and an average price target of $23.71.

Zevra Therapeutics Company Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.